Javascript is not enabled.

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again.

Skip to content
Content starts here
CLOSE ×
Search
CLOSE ×
Search
BRANDAMP
by AARP
Brought to you by
Leaving AARP.org Website

You are now leaving AARP.org and going to a website that is not operated by AARP. A different privacy policy and terms of service will apply.

Life With ATTR Amyloidosis: Turning Uncertainty Into Action 

Scott and Kelly share their journeys from diagnosis to treatment


Scott sharing his personal health journey with wild type attr cardiac amyloidosis
PHOTO CREDIT: Alnylam Pharmaceuticals

For many people living with ATTR (transthyretin amyloidosis)—an underdiagnosed disease that involves the buildup of TTR amyloid in the body1—one thought that can linger after diagnosis is: I wish I had known sooner. Earlier answers can mean earlier treatment—and a jump-start toward slowing the progression of certain types and symptoms of ATTR.2,3 Scott and Kelly know this all too well. Both spent years trying to make sense of seemingly unrelated symptoms, before learning they were living with forms of this rare disease.

Now, they’re using their experiences to help others recognize symptoms and take action sooner.

Scott’s Journey: A Fighter, Through and Through

Scott is a loving husband and happily retired from the medical field. A dedicated martial arts trainee and fighter for more than 25 years, he has always believed that the timing of a kick or block is the difference between winning and losing. In many ways, he learned that timing is just as critical in life and health.

After surviving a rare form of skin cancer, Scott believed he’d already faced the health battles of a lifetime. But over the years, he experienced symptoms that didn’t seem related and had no easy explanation. Carpal tunnel syndrome that required multiple surgeries, shortness of breath, and dizzy spells.4 After hearing Scott was on to his 4th carpal tunnel surgery5, his cardiologist ordered a nuclear imaging test of his heart and the results were unexpected: ATTR amyloidosis with cardiomyopathy (ATTR-CM).2 Looking back, his symptoms had likely started 17 years earlier.

Much like he’d approached his training in martial arts, Scott decided he wouldn’t give in to this new opponent. “I dug in and began researching medical solutions to these challenges and I worked with specialists to get more answers,” Scott reflected. After consulting with his healthcare team, Scott began his treatment journey with AMVUTTRA® (vutrisiran), a treatment for ATTR-CM, with the goal of slowing the progression of this disease.6

kelly sharing her health story with amvuttra
PHOTO CREDIT: Alnylam Pharmaceuticals

Kelly’s Story: Turning Loss Into Purpose

Kelly is an accomplished woman of strength, faith, and optimism. She’s earned three degrees, raised two daughters, and built a successful career in life coaching. She’s also endured a family tragedy and years of health issues that have shaped her resilience and drive to keep moving forward for herself and her daughters.

When Kelly’s father passed away suddenly at the age of 39 after experiencing shortness of breath, pain in his legs and feet, and a cough that wouldn’t go away, she and her family were left with only questions. Years later, Kelly and her sisters began to experience similar health issues. “As my sisters and I grew older, we all began to struggle with strange symptoms, similar to what my dad had experienced,” she said. “I was 24 years old when I started suffering from pain and numbness in my feet and ankles.3,7 Sometimes the pain was so bad, I couldn’t even walk.” It wasn’t until years later, after seeing a neurologist specializing in amyloidosis, that a genetic test confirmed Kelly’s diagnosis of hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN).2,3 “This explained so much! Immediately I thought of my Dad,” Kelly shared. “I believe this is what he had and I believe this is what ultimately took his life.”

Over time, Kelly also developed cardiac symptoms.3,8 After working closely with her specialist, they decided on treatment with AMVUTTRA, which treats hATTR-PN, as well as ATTR-CM.6 With AMVUTTRA, Kelly can take a medication to slow the progression of both nerve and heart damage caused by hereditary ATTR.

The Potential of Slowing Progression and Moving Forward

In ATTR amyloidosis, transthyretin proteins misfold in the blood and build up as amyloid deposits in the body.9-13 AMVUTTRA is a silencer therapy that treats both ATTR-CM and hATTR-PN. As a silencer, it works by decreasing the amount of TTR protein produced in the liver, meaning less can misfold and build up as amyloid deposits in the body.9,10,14,15 AMVUTTRA can cause low vitamin A levels, which can affect vision, so daily vitamin A supplementation is recommended. Other side effects include pain in the arms or legs, pain in the joints, and shortness of breath.6 So, what has this treatment meant for Scott and Kelly? “Knowing there are FDA-approved treatments available and specialists who are well-versed in these options gives me hope—not just for myself, but for others who may face this diagnosis in the future,” Scott shared. 

Kelly continues to consult with her doctors about her symptoms but remains positive. “Since my diagnosis, I have made choices that allow me to focus on my health and on building a better life for my daughters,” she noted. “I’d like other patients who may be battling this condition to know that you don’t have to let it define you.”

See below for safety information and click here to learn more about ATTR-CM, hATTR-PN, and treatment with AMVUTTRA.

Indications

What is AMVUTTRA® (vutrisiran)?

AMVUTTRA is a prescription medicine that treats the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce heart-related death, hospital stays and urgent visits.
  • polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

Important Safety Information

What are the most important things I should know about AMVUTTRA?

AMVUTTRA can cause low vitamin A levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch  or call 1-800-FDA-1088.

For additional information about AMVUTTRA, please see the full Prescribing Information.

References:

1. Hawkins et al. Ann Med. 2015;47(8):625-638.

2. Kittleson et al. Circulation. 2020;142(1):e7-e22.

3. Kittleson et al. J Am Coll Cardiol. 2023;81(11):1076-1126.

4. Maurer et al. Circ Heart Fail. 2019;12(9):e006075.

5. Elzinga et al. Plast Reconstr Surg Glob Open. 2023;11:1-8.

6. AMVUTTRA Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.

7. Adams et al. J Neurol. 2021;268(6):2109-2122.

8. Lovely et al. J Patient Rep Outcomes. 2021;5(3):1-10.

9. Bezerra et al. Front Mol Neurosci. 2020;13:592644.

10. Ando et al. Orphanet J Rare Dis. 2013;8(1):31.

11. Griffin et al. Circ Res. 2021;128:1554-1575.

12. Koike et al. Neurol Ther. 2020;9:317-333.

13. Gonzalez-Duarte et al. Int J Mol Sci. 2021;22:1-10. 

14. Data on file. Alnylam Pharmaceuticals, Inc.

15. Fontana et al. N Engl J Med. 2025;392(1):33-44.

AMV-USA-01670 

Unlock Access to AARP Members Edition

Join AARP to Continue

Already a Member?

Get instant access to members-only products and hundreds of discounts, a free second membership, and a subscription to AARP the Magazine. Expires 6/4.